Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMPGet Rating) posted its earnings results on Thursday. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09), MarketWatch Earnings reports. Armata Pharmaceuticals had a negative return on equity of 101.97% and a negative net margin of 569.21%.

Shares of ARMP stock traded up $0.14 during trading on Friday, reaching $3.94. 4,607 shares of the company’s stock traded hands, compared to its average volume of 6,045. The stock has a market capitalization of $121.08 million, a P/E ratio of -3.94 and a beta of 1.06. Armata Pharmaceuticals has a 1 year low of $2.82 and a 1 year high of $6.49.

Separately, Zacks Investment Research downgraded shares of Armata Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, March 23rd.

Several hedge funds have recently made changes to their positions in ARMP. Northern Trust Corp purchased a new stake in shares of Armata Pharmaceuticals during the 1st quarter valued at approximately $95,000. Dimensional Fund Advisors LP purchased a new stake in Armata Pharmaceuticals in the 4th quarter worth approximately $72,000. Susquehanna International Group LLP purchased a new stake in Armata Pharmaceuticals in the 4th quarter worth approximately $66,000. Vanguard Group Inc. lifted its stake in Armata Pharmaceuticals by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock worth $1,335,000 after purchasing an additional 10,400 shares in the last quarter. Finally, BlackRock Inc. lifted its stake in Armata Pharmaceuticals by 25.7% in the 4th quarter. BlackRock Inc. now owns 25,860 shares of the company’s stock worth $142,000 after purchasing an additional 5,289 shares in the last quarter. Institutional investors own 4.30% of the company’s stock.

About Armata Pharmaceuticals (Get Rating)

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.

Recommended Stories

Earnings History for Armata Pharmaceuticals (NYSEAMERICAN:ARMP)

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.